中文摘要：

目的 观察阿苯达唑壳聚糖微球（ABZ-CS-MPs）治疗感染细粒棘球蚴（Echinococcus granulosus）小鼠的效果。 方法 220只雄性昆明小鼠，除20只作空白对照组外，其余小鼠各腹腔接种细粒棘球蚴原头节约5 000个，于感染12周后将小鼠随机分为感染对照组（n=20）、ABZ-CS-MPs组、阿苯达唑脂质体（L-ABZ）组和阿苯达唑片剂组，后3组按不同治疗剂量37.5、75.0 和150.0 mg/（kg·次）再分为3小组（每组20只小鼠），每鼠灌胃相应剂量药物，每周3次，每次间隔1 d。感染对照组不作治疗。各组受治鼠于连续治疗12周后处死，称取各鼠细粒棘球蚴的囊湿重，计算各组的囊重抑制率。取各组小鼠肝脏进行大体形态观察。HE染色观察细粒棘球蚴组织病理变化。高效液相色谱法测定小鼠血液和肝组织中阿苯达唑主要代谢产物阿苯达唑亚砜（ABZSX）的浓度。 结果 ABZ-CS-MPs组小鼠棘球蚴囊混浊、实变或钙化程度均较其他治疗组明显。各药物治疗组小鼠棘球蚴囊湿重均显著低于感染对照组［（3.19±2.94）g］（P〈0.05），ABZ-CS-MPs组囊湿重［低剂量至高剂量组分别为（0.28±0.28）、（0.24±0.22）和（0.20±0.19）g］显著低于阿苯达唑片剂组［（0.77±0.74）、（0.55±0.42）和（0.76±0.35）g］（P〈0.05）。ABZ-CS-MPs组小鼠棘球蚴囊重抑制率均为同剂量药物组中最高，低剂量组到高剂量组分别为91.1%、92.6%和93.7%。HE染色结果显示，75.0 mg/（kg·次）ABZ-CS-MPs组细粒棘球蚴组织Ⅰ和Ⅱ级病理变化的小鼠数量最多（15/18）。不同剂量ABZ-CS-MPs组和L-ABZ组细粒棘球蚴组织Ⅰ和Ⅱ级病理变化的小鼠数量均高于同剂量阿苯达唑片剂组（P〈0.05）。高效液相色谱法结果显示，75.0 和150.0 mg/（kg·次）ABZ-CS-MPs组小鼠血液中的ABZSX浓度［（0.83±0.39）和（0.80±0.50）μg/mL］显著高于同剂量L-ABZ组［（0.34±0.03）和（0.43±0.15）μg/

英文摘要：

Objective To observe the therapeutic effect of albendazole chitosan microspheres （ABZ-CS-MPs） on cystic echinococcosis in mice. Methods Two hundred male kunming mice were each infected by intraperitoneal inoculation of about 5 000 viable protoscoleces of Echinococcus granulosus. Another 20 mice were kept as blank control. After 12 weeks post infection, the mice were randomly divided into four groups named as infection control group（n=20）, ABZ-CS-MPs group, albendazole liposome（L-ABZ） group, and albendazole tablet group. The latter three treatment groups were then each divided into three subgroups （n=20） by given the dose of 37.5, 75.0, and 150.0 mg/kg for three times per week, respectively. After 12 weeks of treatment, all mice were sacrificed. The weight of hydatid cysts was measured and the inhibition rate were calculated. Mouse liver was observed. The histopathological changes of E. granulosus were observed by microscopy. The concentration of albendazole sulfoxide in plasma and liver tissues was determined by high-performance liquid chromatography. Results Compared with the other treatment groups, the turbidity of contained fluid, the consolidation level and calcification level of hydatid cysts in ABZ-CS-MPs group were higher. The average weight of hydatid cysts in each treatment group was lower than that of infection control group[（3.19±2.94） g]（P〈0.05）. The cyst weight in 37.5, 75.0, and 150.0 mg/kg ABZ-CS-MPs group[（0.28±0.28）, （0.24±0.22）, and （0.20±0.19） g, respectively] was lower than that of albendazole tablet groups [（0.77±0.74）, （0.55±0.42）, （0.76±0.35） g]（P〈0.05）. Among the same dosage groups, the inhibition rate in ABZ-CS-MPs group（from low to high dosage sub-group： 91.1%, 92.6%, and 93.7%, respectively） was highest. In 75.0 mg/kg ABZ-CS-MPs group, there were 15 mice with classⅠ（degeneration） and Ⅱ（necrosis） pathological changes of E. granulosus hydatid. The number of mice with class Ⅰ and Ⅱ pathological change